A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
Status:
Completed
Trial end date:
2018-12-21
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the effect of treatment with romosozumab for 6 months
compared with placebo on percent changes in bone mineral density (BMD) at the lumbar spine as
assessed by dual-energy X-ray absorptiometry (DXA) in postmenopausal women with osteoporosis.